Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Oceania Healthcare (OCA) / FY24

Capex cut 68% to manage 7.7x leverage; tax benefit inflated NPAT

EBITDA rose just 3.2% on 7.4% revenue growth, while a -10.9% effective tax rate drove NPAT up 104.5% and development capex was paused.

Healthcare / Retirement living

OCA revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $131.6m, versus $260.6m in FY25.

OCA EBITDA margin

EBITDA margin across covered periods.

↗
Loading chart...
  • HY24 OCA: Outside range low ebitda margin. 28.6%; 3-period range 29.1% to 31.7%. EBITDA margin: 28.6%, below normal range; 3-period mean 30.8%, range 29.1%-31.7%.
EBITDA margin: 28.6%, below normal range; 3-period mean 30.8%, range 29.1%-31.7%.

OCA operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $79m, versus $110.3m in FY25.

OCA working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY26 was $0m, versus -$101.1m in HY25.
Release date
24 May 2024
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

FY24 vs FY23

Revenue

$265.5m

+7.4% ↑ vs $247.2m

EBITDA

$82.6m

+3.2% ↑ vs $80m

Net profit after tax

$31.5m

+104.5% ↑ vs $15.4m

Net cash inflow from operating activities

$85.4m

+21.6% ↑ vs $70.2m

Declared dividend per share

—

— vs 1.3c

Total assets

$2.8b

+9.3% ↑ vs $2.5b

What changed

Oceania's headline NPAT doubled to $31.5m (+104.5%), but the move was driven primarily by a tax benefit rather than operating performance: the effective tax rate was -10.9% in FY24, so reported tax expense added to earnings rather than subtracting from them

Profit before tax of $28.4m sits below NPAT, which means the cleaner operating read is materially weaker than the headline. Revenue grew 7.4% to $265.5m and EBITDA grew only 3.2% to $82.6m.

The more economically significant move sits below the P&L. Capex was cut from $164.0m to $52.0m (-68.3%), capex intensity dropped from 66.3% to 19.6% of revenue, and gross borrowings ended at $640.5m with net debt of $633.0m — leverage of 7.7x EBITDA. Operating cash flow rose 21.6% to $85.4m and FCF pre-lease turned positive at $33.4m (versus -$93.8m).

What matters

Development spend was halted to defend the balance sheet

A $112m cut in capex in a single year, for a retirement-village operator whose Village Operations segment depends on new units to generate development margin and DMF, is a strategic shift rather than a timing effect. The pullback funded the positive FCF, not earnings growth.

Headline earnings growth is not repeatable. Stripping the tax benefit, PBT of $28.4m sits below NPAT of $31.5m and EBITDA grew only 3.2%. Investors should anchor on PBT and EBITDA trends, not the 104.5% NPAT figure, when judging operating momentum. Care Operations (77.8% of revenue) earned a derived segment margin of just 5.8%, so the group result still leans on Village Operations economics.

Leverage of 7.7x EBITDA constrains flexibility. With net debt at $633.0m, $7.5m of cash, and ROE of just 3.1%, the company has limited capacity to simultaneously fund development, service debt, and pay dividends at prior levels. The FY24 dividend declared in this release is not disclosed in the extraction, against 1.3 cps in the comparable, which itself signals a tightening capital posture.

Expectations

No forward targets or guidance are supplied in this release

HY24 generated revenue of $131.6m (49.6% of the full year) and EBITDA of $37.6m (45.6%), so revenue was roughly balanced first-half/second-half while EBITDA was second-half weighted. HY24 NPAT of $35.2m exceeded the full-year $31.5m, implying a second-half NPAT loss of roughly $3.7m once tax benefits and revaluation effects unwound — confirming that the doubling in reported NPAT is concentrated in the first half and partly reverses in the second.

This release does not support a clean read on a return to a normalised development cadence, on dividend resumption, or on the leverage trajectory. Those remain open.

Quality of result

Operating cash quality, narrowly defined, improved: OCF/EBITDA was 103.4% versus 87.7% prior, and FCF pre-lease of $33.4m equated to 106.0% of NPAT

However, FCF turned positive primarily because capex was cut by $112m, not because earnings rose. That means the cash improvement is not a durability signal — it is a deliberate slowdown in growth investment, which lowers future development margin and resale capacity.

The NPAT line itself is heavily timing-driven: a -10.9% effective tax rate (tax benefit) added several million dollars that will not recur on the same scale, and the disclosed gains include $67.9m of capital gains within the result. Underlying EBITDA growth of 3.2% on 7.4% revenue growth implies a margin contraction, consistent with cost pressure outpacing pricing. Trade debtors at $124.9m represent 171.7 receivable days, which is high in absolute terms but typical of retirement-village receivables tied to resident loan and resale settlement timing rather than ordinary trade debt.

Unresolved

Open questions

Will FY24 dividends be declared and at what payout against the 30–50% policy band, and what is the implication for the company's capital posture?
How quickly does management intend to restart development capex, and what unit-delivery cadence is being planned for FY25 and FY26?
What drove the -10.9% effective tax rate, and is any portion of that benefit expected to recur?
What is the deleveraging path from 7.7x net debt / EBITDA, and what level of leverage does management consider sustainable through the cycle?
Why did the "Other" segment record a $24.0m loss, and is that cost base structural?

This briefing cannot assess Oceania's underlying property revaluation movements, ORA and resident-loan flows, or unit sales pricing dynamics, because those line items are not provided in the supplied extraction.

Chat

Ask about OCA FY24

Ask follow-up questions about Oceania Healthcare's FY24 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about OCA FY24

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Oceania Healthcare's FY24 result.

Will FY24 dividends be declared and at what payout against the 30–50% policy band, and what is the implication for the company's capital posture?Why does "Development spend was halted to defend the balance sheet" matter?How strong was the cash and earnings quality in FY24?What should I watch next for OCA after FY24?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Annual Report

FY24 / financial report↗

Prior comparable period

Media Release

FY23 / financial report↗

Results Announcement

FY23 / results announcement↗

Interim context

Interim Report

HY24 / financial report↗

Investor Presentation

HY24 / results presentation↗

Media Release

HY24 / media release↗

Results Announcement

HY24 / results announcement↗

Release context

Investor Presentation

FY24 / commentary↗

CEO Address

HY24 / commentary↗

Chair Address

HY24 / commentary↗

Presentation

HY24 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Leverage and balance-sheet risk

Net debt / EBITDA is 7.70x for this result.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.0pp, with a distortion flag in the result.

→

Cash conversion quality

This result converted 103.4% of EBITDA to operating cash flow, +15.7pp versus the prior comparable period.

→

Working-capital pressure

Debtor days were 172 days for this result.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when OCA publishes next

Get the next Oceania Healthcare briefing and related NZX reporting-season updates by email.